Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
UPDATE: RBC Capital Issues Positive Comments on Akebia Therapeutics (AKBA), Believes Shares Could Trade Up $5 to $8 on Data
May 5, 2020 9:24 AM EDT(Updated - May 5, 2020 9:25 AM EDT)
(expanding comment)
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Akebia Therapeutics (NASDAQ: AKBA)
The analyst comments "This morning AKBA announced positive topline results from the ph3 INNO2VATE studies (n=3,902) of vadadustat... More
Akebia Therapeutics (AKBA) Tops Q1 EPS by 15c
May 5, 2020 7:43 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More